Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice

PloS One
Yan WengSaswata Talukdar

Abstract

Pharmacological administration of fibroblast growth factor 21 (FGF21) improves metabolic profile in preclinical species and humans. FGF21 exerts its metabolic effects through formation of beta-klotho (KLB)/FGF receptor 1c FGFR1c complex and subsequent signaling. Data from various in vitro systems demonstrate the intact C- and N-terminus of FGF21 is required for binding with KLB, and interaction with FGFR1c, respectively. However the relative roles of the termini for in vivo pharmacological effects are unclear. Here we report PF-05231023, a long-acting FGF21 analogue which is unique in that the half-life and subcutaneous (s.c.) bioavailability of the intact C-terminus are significantly different from those of the intact N-terminus (2 vs. 22 hr for half-life and 4~7 vs. ~50% SC bioavailability). Therefore, this molecule serves as a valuable tool to evaluate the relative roles of intact C-terminus vs. N-terminus in in vivo pharmacology studies in preclinical species. We determined the effects of PF-05231023 administration on body weight (BW) loss and glucose reduction during an oral glucose tolerance test (OGTT) following SC and intravenous (i.v.) administration in diet-induced obese (DIO) and leptin-deficient obese (ob/ob) mice, ...Continue Reading

References

May 20, 2005·The Journal of Clinical Investigation·Alexei KharitonenkovArmen B Shanafelt
Sep 13, 2007·International Journal of Obesity : Journal of the International Association for the Study of Obesity·K D Hall
Aug 9, 2008·Endocrinology·Tamer CoskunAlexei Kharitonenkov
Oct 9, 2008·Diabetes Care·Sebastian SteinMathias Fasshauer
Jan 1, 2009·Journal of Cellular Physiology·Radmila MicanovicAlexei Kharitonenkov
Sep 19, 2009·PLoS Computational Biology·Juen Guo, Kevin D Hall
Nov 13, 2009·The American Journal of Clinical Nutrition·Steven A Kliewer, David J Mangelsdorf
Jul 30, 2010·Molecular Endocrinology·Klementina Fon TacerSteven A Kliewer
Jan 5, 2011·Trends in Endocrinology and Metabolism : TEM·Alexei Kharitonenkov, Philip Larsen
Dec 30, 2011·Nature Methods·Matthias H TschöpEric Ravussin
Feb 4, 2012·Genes & Development·Ffolliott M FisherBruce M Spiegelman
Jun 8, 2012·PloS One·Andrew C AdamsAlexei Kharitonenkov
Jul 14, 2012·PloS One·Murielle M VéniantDavid J Lloyd
Sep 11, 2012·Cell Metabolism·Xunshan DingSteven A Kliewer
Feb 14, 2013·Nature Reviews. Molecular Cell Biology·Regina Goetz, Moosa Mohammadi
Mar 5, 2013·The Journal of Biological Chemistry·Min LuJerrold M Olefsky
Mar 29, 2013·PloS One·Alexei KharitonenkovDavid E Moller
May 15, 2013·Cell Metabolism·William L HollandPhilipp E Scherer
May 31, 2013·The Journal of Pharmacology and Experimental Therapeutics·Jie HuangNancy Levin
Sep 10, 2013·Cell Metabolism·Marc L Reitman
Sep 10, 2013·Cell Metabolism·Gregory GaichDavid E Moller
Apr 9, 2014·Trends in Endocrinology and Metabolism : TEM·Ruth E Gimeno, David E Moller

❮ Previous
Next ❯

Citations

Jan 5, 2016·Cell Metabolism·Saswata TalukdarSteven A Kliewer
Nov 17, 2015·Nature Reviews. Drug Discovery·Chiara DegirolamoAntonio Moschetta
May 6, 2015·British Journal of Clinical Pharmacology·Jennifer Q DongRoberto A Calle
Sep 30, 2015·Molecular and Cellular Endocrinology·Marta GiraltFrancesc Villarroya
Jun 4, 2016·Nature Reviews. Drug Discovery·Christine M KusminskiPhilipp E Scherer
Nov 24, 2016·Journal of Internal Medicine·A Kharitonenkov, R DiMarchi
Aug 15, 2018·PloS One·Tod TurnerMylène Perreault
Jun 1, 2017·American Journal of Physiology. Endocrinology and Metabolism·Ting Xie, Po Sing Leung
Sep 2, 2016·Hormone Molecular Biology and Clinical Investigation·Albert Pérez-MartíJoana Relat
May 20, 2017·Hormone Molecular Biology and Clinical Investigation·Junichiro SonodaAmos Baruch
Aug 30, 2017·Hormone Molecular Biology and Clinical Investigation·Marcel ScheidelerAnastasia Georgiadi
Jun 20, 2016·Hormone Molecular Biology and Clinical Investigation·Daniel Cuevas-Ramos, Carlos A Aguilar-Salinas
Jul 14, 2016·Journal of Pharmacokinetics and Pharmacodynamics·W Clayton ThompsonCynthia J Musante
Sep 25, 2019·International Journal of Molecular Sciences·Úrsula Martínez-GarzaJoana Relat
Apr 14, 2020·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Min GongLigang Zhou
Aug 9, 2020·Nature Reviews. Endocrinology·Leiluo GengAimin Xu
Jan 1, 2021·Critical Reviews in Clinical Laboratory Sciences·Yasaman Badakhshi, Tianru Jin
Jan 1, 2021·Molecular Metabolism·Saswata Talukdar, Alexei Kharitonenkov
Dec 6, 2020·Biologicals : Journal of the International Association of Biological Standardization·Daejin KimDae Kyong Kim
Jun 29, 2021·The Lancet. Diabetes & Endocrinology·Michael A NauckJuris J Meier
Jun 14, 2021·Reviews in Endocrine & Metabolic Disorders·Shuang HuaDewei Ye

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
ELISAs

Software Mentioned

WinNonlin

Related Concepts

Related Feeds

Asprosin

Asprosin is a fasting-induced hormone produced in the white adipose tissue to stimulate the hepatic release of glucose into the bloodstream. Discover the latest research on this protein hormone here.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.